Quest Diagnostics (DGX) vs Molina Healthcare (MOH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Quest Diagnostics (DGX) has outperformed Molina Healthcare (MOH) over the past year, gaining 27.6% versus a loss of 3.5%. Over five years, DGX leads with a +62.0% price change compared with -30.1% for MOH. Quest Diagnostics is the larger company by market cap ($25.49 billion vs $10.28 billion), about 2.5 times the size.
On valuation, Quest Diagnostics trades at a lower forward P/E (19.2x vs 20.2x for Molina Healthcare). Quest Diagnostics pays a dividend yielding 1.44%, while Molina Healthcare does not currently pay one. Quest Diagnostics converts more of its revenue into profit, with a net margin of 9.0% versus 1.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DGX | MOH |
|---|---|---|
| Share price | $230.97 | $196.93 |
| Market cap | $25.49B | $10.28B |
| 1-day change | +0.07% | +0.60% |
| YTD return | +33.01% | +12.80% |
| 1-year return | +27.60% | -3.53% |
| 5-year return | +61.97% | -30.11% |
| P/E ratio (TTM) | 24.52 | — |
| Forward P/E | 19.19 | 20.21 |
| EPS (TTM) | $9.42 | $0.09 |
| Dividend yield | 1.44% | 0.00% |
| Annual dividend | $3.32 | $0.00 |
| Revenue (latest FY) | $11.04B | $45.43B |
| Revenue growth (YoY) | +11.78% | +11.75% |
| Net income (latest FY) | $992.00M | $472.00M |
| Gross margin | 33.21% | 13.07% |
| Operating margin | 14.10% | 1.72% |
| Net margin | 8.99% | 1.04% |
| 52-week high | $248.84 | $244.89 |
| 52-week low | $171.18 | $121.06 |
| Distance from 52-week high | -7.18% | -19.58% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +7.40% | +6.19% |
| Average volume | 1.04M | 914.54K |
| Shares outstanding | 110.37M | 52.20M |
| Employees | 46,000 | 19,000 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Quest Diagnostics is about 2.5 times larger than Molina Healthcare by market value ($25.49B vs $10.28B).
- DGX has outperformed MOH by 31.1 percentage points over the past year.
- Quest Diagnostics offers a meaningfully higher dividend yield (1.44% vs 0.00%).
- Quest Diagnostics is more profitable, keeping 9.0 cents of every revenue dollar as net income versus 1.0 cents for Molina Healthcare.
About Quest Diagnostics
DGX stock →Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
Health Care · Medical Specialities · 46,000 employees
About Molina Healthcare
MOH stock →Molina Healthcare, Inc. provides managed healthcare services to low-income families and individuals under the Medicaid and Medicare programs and through the state insurance marketplaces in the United States.
Health Care · Medical Specialities · 19,000 employees
DGX vs MOH FAQ
Which is bigger, Quest Diagnostics or Molina Healthcare?
Quest Diagnostics (DGX) is larger, with a market capitalization of $25.49B compared with $10.28B for Molina Healthcare (MOH).
Which stock has performed better over the past year, DGX or MOH?
DGX returned +27.60% over the past 12 months, compared with -3.53% for MOH (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Quest Diagnostics or Molina Healthcare?
Quest Diagnostics pays a dividend yielding 1.44%, while Molina Healthcare does not currently pay a regular dividend.
Are Quest Diagnostics and Molina Healthcare in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.